APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015
Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013
A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Source: Eur Respir J 2016; 47: 490-498 Year: 2016
Omalizumab in patients with allergic bronchopulmonary aspergillosis (ABPA): a multicenter case series study in Spain Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009
The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Source: Eur Respir J, 52 (3) 1801159; 10.1183/13993003.01159-2018 Year: 2018
Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007
Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012
A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007
Subcutaneous anti-immunoglobulin E (Omalizumab) as a steroid-sparing agent in allergic asthma – a systematic review of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis Source: Eur Respir J , 49 (3) 1602486; DOI: 10.1183/13993003.02486-2016 Year: 2017
A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021